This trial uses two existing cancer drugs to see if jointly they increase the survival rate.
Given the ugly side effects, and the liklihood that a marginal but improved outcome is found - I would call this a complimentary treatment to cvac, and possibly subordinate.
The main competition I see (and again it will probably be complimentary) is NV-128 by Novogen but hasn't begun human trials yet.
One of the main pluses to cvac is doesn't have the nasty side effects of chemo and the drugs in the trial above.
competition, page-2
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
-0.005(1.72%) |
Mkt cap ! $413.9M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.5¢ | 28.0¢ | $1.441M | 5.001M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 102393 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 14707 | 1 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |